
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Diego - A network of teledermatology links throughout Alaska is providing cost-effective, timely access to dermatologic care for indigenous peoples in the nation's most underserved and sprawling state, its designer reports.